Physician profile
Eric Liu
NPI 1609865377
$3,242.44
in general payments reported to CMS, 2019-2025
26 companies · $2,003 in 2025
The $2,003 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $111 · 2021: $30.58 · 2022: $123 · 2023: $177 · 2024: $263 · 2025: $2,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,647 · Food and Beverage: $796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,647.44 |
| Food and Beverage | $796.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $1,047.15 | 2025 | Iovera |
| Histosonics, INC. | $667.10 | 2025 | |
| Amgen INC. | $229.76 | 2019-2025 | Evenity, Prolia, Otezla |
| Astrazeneca Pharmaceuticals Lp | $219.64 | 2019-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $213.82 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Abbvie INC. | $112.81 | 2022-2024 | |
| Novo Nordisk INC | $110.88 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $91.58 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $72.58 | 2024-2025 | |
| Gilead Sciences, INC. | $66.35 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $45.24 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Exact Sciences Corporation | $39.89 | 2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $38.31 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Antares Pharma, INC. | $34.70 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.15 | 2023-2024 | Jardiance |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $30.18 | 2020-2021 | |
| Astellas Pharma US INC | $29.41 | 2020 | |
| Medtronic, INC. | $22.33 | 2025 | Symplicity G3 |
| Sanofi-Aventis U.S. LLC | $22.18 | 2025 | |
| Sun Pharmaceutical Industries INC. | $22.14 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.31 | 2022 | |
| Abbott Laboratories | $19.29 | 2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $16.66 | 2022 | |
| Alexion Pharmaceuticals, INC. | $15.19 | 2019 | |
| Duchesnay USA Incorporated | $11.92 | 2019 | |
| Daiichi Sankyo INC. | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.